4D Molecular Therapeutics Inc (FDMT) Stock Price, Quote & News

Company Profile

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macu...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 505 2680

Website: www.4dmoleculartherapeutics.com

Address:

5858 Horton Street, Suite 455, EmeryVille, United States

vulture2 May. 13 at 11:58 AM

No, 4D Molecular Therapeutics $FDMT did not file a $400 million S-3 on Friday.Instead, the company filed an S-3 Registration Statement with the SEC on Thursday, May 7, 2026, for an aggregate amount of $200 million.Key operational details of this specific filing include:Purpose: It functions entirely as a replacement shelf registration. It is transferring $200 million of unsold securities from an expiring August 2023 S-3 filing (set to lapse on August 15, 2026).Dilution Impact: Because this filing simply carries forward previously registered, unsold capacity under SEC Rule 415(a)(6), it does not represent a newly added dilution event or an expansion of their existing capital-raising limits.

0 · Reply

ReturnOfEsquire May. 11 at 3:00 PM

$FDMT The company filed a 400M S-3 Friday.

1 · Reply

BillionerOfKing May. 11 at 2:20 PM

$FDMT Current Stock Price: $11.02 Contracts to trade: $11.0 FDMT May 15 2026 Call Entry: $0.45 Exit: $0.72 ROI: 59% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Lukey63 May. 5 at 6:35 PM

$FDMT 23% SI. Ripe for a squeeze.

0 · Reply

Teillbou May. 4 at 10:50 PM

$FDMT 4D-150 better than regenxbio rgx-314 ?

1 · Reply

Xxxxcccemre Apr. 30 at 11:20 AM

$FDMT I missed my baby , it’s coming close to crunch time soon. Can’t wait. Watching for a rentry

1 · Reply

BananaRockSecurities Apr. 27 at 11:37 PM

$FDMT grabbed a 1000 shares today. Let's see how she goes

0 · Reply

laaarsas Apr. 26 at 2:00 PM

$FDMT Indeed, we find this one tricky! Can someone help us?

0 · Reply

laaarsas Apr. 25 at 2:13 PM

$FDMT How important is the Q2 data coming?

0 · Reply

SuperGreenToday Apr. 22 at 11:40 PM

$FDMT Share Price: $9.81 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $1.66 – $2.05 Target Zone: $2.71 – $3.31 Potential Upside: 54% ROI Time to Expiration: 176 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

4D Molecular price target lowered to $33 from $38 at Goldman Sachs

2026-05-07T22:48:23.000Z - 5 days ago

4D Molecular files $400M mixed securities shelf

May 7, 2026, 4:05 PM EDT - 5 days ago

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

May 4, 2026, 8:00 AM EDT - 9 days ago

4DMT to Participate in Upcoming Investor Conferences

Apr 17, 2026, 4:05 PM EDT - 25 days ago

4DMT Announces New Employment Inducement Grants

2026-04-13T13:56:19.000Z - 4 weeks ago

4D Molecular price target lowered to $23 from $45 at Evercore ISI

2026-03-30T13:08:58.000Z - 6 weeks ago

4D Molecular assumed with a Buy at Jefferies

Mar 18, 2026, 4:05 PM EDT - 7 weeks ago

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Mar 16, 2026, 8:00 AM EDT - 2 months ago

4DMT to Participate in Upcoming Investor Meetings

Mar 12, 2026, 9:00 AM EDT - 2 months ago

4D Molecular Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 4:20 PM EDT - 2 months ago

4D Molecular Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 10:30 AM EST - 2 months ago

4D Molecular Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-09T13:26:19.000Z - 3 months ago

4D Molecular completes enrollment for 4FRONT-1 Phase 3 trial

Feb 9, 2026, 8:00 AM EST - 3 months ago

4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD

2026-01-27T21:27:44.000Z - 3 months ago

4D Molecular assumed with an Overweight at Barclays

2026-01-19T18:35:06.000Z - 4 months ago

4D Molecular announces employment inducement grants

Jan 14, 2026, 10:30 AM EST - 4 months ago

4D Molecular Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 8:00 AM EST - 4 months ago

4DMT Provides Company Update and Anticipated Development Milestones for 2026

Dec 17, 2025, 8:00 AM EST - 5 months ago

4D Molecular Therapeutics Transcript: Study Result

2025-12-17T12:05:14.000Z - 5 months ago

4D Molecular announces interim data from 4D-710 Phase 1 AEROW trial

Dec 17, 2025, 7:00 AM EST - 5 months ago

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

Dec 8, 2025, 8:00 AM EST - 5 months ago

4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 2:35 PM EST - 5 months ago

4D Molecular Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 20, 2025, 8:00 AM EST - 6 months ago

4DMT to Participate in 8th Annual Evercore Healthcare Conference

Nov 18, 2025, 4:00 AM EST - 6 months ago

4D Molecular Therapeutics Transcript: Jefferies London Healthcare Conference 2025

2025-11-17T11:10:33.000Z - 6 months ago

4D Molecular names Kristian Humer as CFO

Nov 17, 2025, 6:00 AM EST - 6 months ago

4DMT Appoints Kristian Humer as Chief Financial Officer

2025-11-11T14:25:18.000Z - 6 months ago

4D Molecular price target raised to $32 from $26 at RBC Capital

2025-11-11T10:25:26.000Z - 6 months ago

4D Molecular price target lowered to $33 from $38 at Barclays

Nov 10, 2025, 8:00 AM EST - 6 months ago

4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

2025-11-07T00:00:16.000Z - 6 months ago

4D Molecular upgraded to Equal Weight from Underweight at Morgan Stanley

Nov 6, 2025, 4:05 PM EST - 6 months ago

4DMT to Participate in Jefferies 2025 London Healthcare Conference

2025-11-06T12:52:34.000Z - 6 months ago

4D Molecular’s 4D-150 shows efficacy in Phase 1/2 wet AMD trial

Nov 6, 2025, 6:23 AM EST - 6 months ago

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

Nov 6, 2025, 6:00 AM EST - 6 months ago

4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years

2025-10-31T09:30:34.000Z - 6 months ago

4D Molecular announces 4D-150 license agreement with Otsuka Pharmaceutical

Oct 30, 2025, 11:02 PM EDT - 6 months ago

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

Oct 21, 2025, 2:00 PM EDT - 7 months ago

4D Molecular Therapeutics Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Oct 21, 2025, 9:30 AM EDT - 7 months ago

4D Molecular Therapeutics Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Oct 14, 2025, 8:00 AM EDT - 7 months ago

4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference

2025-10-13T12:06:37.000Z - 7 months ago

4D Molecular announces CF Foundation will provide $11M for 4D-710

Oct 13, 2025, 8:00 AM EDT - 7 months ago

4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation

Sep 9, 2025, 1:50 PM EDT - 8 months ago

4D Molecular Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 10:00 AM EDT - 8 months ago

4D Molecular Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 11:30 AM EDT - 8 months ago

4D Molecular Therapeutics Transcript: Cantor Global Healthcare Conference 2025

2025-09-02T12:30:08.000Z - 9 months ago

4D Molecular appoints Clark as CMO, Zhu as SVP, CMO Kim to step down

Sep 2, 2025, 8:00 AM EDT - 9 months ago

4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness

Aug 13, 2025, 2:30 PM EDT - 9 months ago

4D Molecular Therapeutics Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 11, 2025, 8:00 AM EDT - 9 months ago

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Aug 6, 2025, 8:00 AM EDT - 10 months ago

4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 31, 2025, 4:05 PM EDT - 10 months ago

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

Jul 24, 2025, 8:00 AM EDT - 10 months ago

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists

Jul 2, 2025, 4:05 PM EDT - 11 months ago

4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution

Jun 11, 2025, 11:20 AM EDT - 1 year ago

4D Molecular Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 3:45 PM EDT - 1 year ago

4D Molecular Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 14, 2025, 5:20 PM EDT - 1 year ago

4D Molecular Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 8, 2025, 4:05 PM EDT - 1 year ago

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

May 1, 2025, 8:00 AM EDT - 1 year ago

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

Apr 3, 2025, 9:15 AM EDT - 1 year ago

4D Molecular Therapeutics Transcript: RBC Inaugural Virtual Ophthalmology Conference

Mar 12, 2025, 10:00 AM EDT - 1 year ago

4D Molecular Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 11, 2025, 10:00 AM EDT - 1 year ago

4D Molecular Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 8:00 AM EDT - 1 year ago

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

Feb 28, 2025, 4:05 PM EST - 1 year ago

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Feb 10, 2025, 8:00 AM EST - 1 year ago

4D Molecular Therapeutics Transcript: Study Result

Feb 8, 2025, 2:30 PM EST - 1 year ago

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

Dec 3, 2024, 1:45 PM EST - 1 year ago

4D Molecular Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 19, 2024, 7:00 AM EST - 1 year ago

4D Molecular Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 13, 2024, 4:05 PM EST - 1 year ago

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

vulture2 May. 13 at 11:58 AM

0 · Reply

ReturnOfEsquire May. 11 at 3:00 PM

$FDMT The company filed a 400M S-3 Friday.

1 · Reply

BillionerOfKing May. 11 at 2:20 PM

0 · Reply

Lukey63 May. 5 at 6:35 PM

$FDMT 23% SI. Ripe for a squeeze.

0 · Reply

Teillbou May. 4 at 10:50 PM

$FDMT 4D-150 better than regenxbio rgx-314 ?

1 · Reply

Xxxxcccemre Apr. 30 at 11:20 AM

$FDMT I missed my baby , it’s coming close to crunch time soon. Can’t wait. Watching for a rentry

1 · Reply

BananaRockSecurities Apr. 27 at 11:37 PM

$FDMT grabbed a 1000 shares today. Let's see how she goes

0 · Reply

laaarsas Apr. 26 at 2:00 PM

$FDMT Indeed, we find this one tricky! Can someone help us?

0 · Reply

laaarsas Apr. 25 at 2:13 PM

$FDMT How important is the Q2 data coming?

0 · Reply

SuperGreenToday Apr. 22 at 11:40 PM

0 · Reply

MOTP Apr. 22 at 12:46 PM

$FDMT What’s the Q1Ear date for this one?

0 · Reply

jimbecker Apr. 8 at 1:47 PM

$FDMT Looks like a good setup. Starting with 100 shares.

0 · Reply

vu_jade Apr. 7 at 6:22 PM

$FDMT hello

0 · Reply

vu_jade Apr. 1 at 5:23 PM

$FDMT here for another run

0 · Reply

SuperGreenToday Mar. 28 at 2:56 AM

$FDMT Share Price: $9.32 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $1.61 – $1.99 Target Zone: $2.71 – $3.31 Potential Upside: 58% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

NorthStarStats Mar. 27 at 10:38 AM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. Scanner only pulled 5 stocks; this is a warning sign for momentum traders. Tighten stops, look for follow through volume. $AGIO Score: 98, $BMEA Score: 98, $FDMT Score: 90, $CNTA Score: 70, $KALV Score: 65

0 · Reply

ReturnOfEsquire Mar. 26 at 3:28 PM

$FDMT Big volume today. I'm struggling to predict this action anymore.

2 · Reply

ReturnOfEsquire Mar. 25 at 3:45 PM

$FDMT Pretty quick nearly 20% move.

2 · Reply

Quantumup Mar. 24 at 12:59 PM

H.C. Wainwright⬆️ $SRZN PT to $36/reiterated at Buy. $EYPT $OCUL $FDMT $REGN RHHBY KOD Here's what H.C. Wainwright had to say in its note: https://x.com/Quantumup1/status/2036427176845640179?s=20

0 · Reply

JoeNolff6 Mar. 23 at 2:40 PM

$FDMT I believe the upgrades are for a buyout. Stated early by someone else, no new readouts till end of this year and beginning of next. So, I think this will be bought out this year and sooner than later, way too valuable of a company for a big biotech not to grab it up asap.

2 · Reply

grizzly3 Mar. 19 at 6:06 PM

$FDMT Unbelievable. At the end of 2025 I was urging people to sell at $11–$12 and got nothing but insults. Now suddenly the same logic appears.

0 · Reply

ReturnOfEsquire Mar. 19 at 4:25 PM

$FDMT They are going to rip this down further. They took it up to close their shorts, repeat. Still a year+ from pivotal data.

0 · Reply

Market Cap	564.06M
Revenue (ttm)	85.21M
Net Income (ttm)	-140.11M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-164.43%
Debt to Equity Ratio	0.00

Volume	458,800
Avg Vol	740,398
Day's Range	N/A - N/A
Shares Out	52.28M
Stochastic %K	66%
Beta	2.77
Analysts	Strong Sell
Price Target	$28.22